Wuxi Pharmaceutical Ming Kand conducted a series of share repurchase activities from March 8 to April 22, 2024. According to the company's disclosure, the company repurchased several shares in a total of several million shares during the above period. The repurchase price presents a different degree of discount or premium compared to the market price. None of these share repurchases involve share write-offs. The company had 2,546,260,847 shares outstanding on April 22. According to the report, Pharma Kund has complied with the relevant listing rules requirements and confirmed that all transactions are conducted in accordance with the regulations. Director Li Keung submitted relevant documents on behalf of the company.

Wuxi Pharmaceutical Ming Kand conducted a series of share repurchase activities from March 8 to April 22, 2024. According to the company's disclosure, the company repurchased several shares in a total of several million shares during the above period. The repurchase price presents a different degree of discount or premium compared to the market price. None of these share repurchases involve share write-offs. The company had 2,546,260,847 shares outstanding on April 22. According to the report, Pharma Kund has complied with the relevant listing rules requirements and confirmed that all transactions are conducted in accordance with the regulations. Director Li Keung submitted relevant documents on behalf of the company.